Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Efficacy and Safety of GC3110B vs GCFLU Quadrivalent in Healthy Adults
NCT02915809Phase 3Unknown
- Sponsor
- GC Biopharma
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of GC3110B in influenza (2 arms), sponsored by GC Biopharma. Primary endpoint: Geometric Mean Titer Ratios of Antibodies at Day 21. Status: unknown.
02
Drugs
GC3110B
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02915809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915809.